A Safety Study for MSB0010445 in Combination With Stereotactic Body Radiation in Advanced Melanoma Subjects Following Prior Treatment With Ipilimumab

Trial Profile

A Safety Study for MSB0010445 in Combination With Stereotactic Body Radiation in Advanced Melanoma Subjects Following Prior Treatment With Ipilimumab

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs MSB 0010445 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors EMD Serono
  • Most Recent Events

    • 09 Oct 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 15 Apr 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2015 as per ClinicalTrials.gov record.
    • 15 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top